LeMaitre Vascular Stock Price and Value Analysis

LeMaitre Vascular (NasdaqGM:LMAT) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold LeMaitre Vascular to reach your target.

Target type

LMAT Free Cash Flow Trend

Free Cash Flow trendline for LMAT
Free Cash Flow trendline for LeMaitre Vascular
CSV

Based on historical returns, we believe that LeMaitre Vascular can grow its free cash at a rate of about 8%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a decent rate.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company has a low dividend yield.

Inside the LMAT Numbers

LMAT Price
(LeMaitre Vascular stock price per share)
$73.61
[?] LMAT Fair Price
(based on intrinsic value)
$17.20
[?] LMAT Safety Price (based on a variable margin of safety) $10.32
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 35% higher than other Healthcare stocks
[?] PE Ratio versus Industry 63% higher than other Medical Devices stocks
[?] Free Cash Flow Jitter 52%
[?] Dividend Yield 1.27% (tax impact)
Shares Shorted 1,656,867

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-21.

The six months before that had 0 buys and 7 sales.

Recent Insider Activity

Open-market buys and sells reported by LeMaitre Vascular's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-05-08 LeMaitre George W (Chairman and CEO) Sell 27,881 $108.69
2026-05-08 Kamke Trent G (Senior V. P., Operations) Sell 2,928 $107.00
2026-05-07 Jasinski Lawrence J Sell 3,943 $110.00
2026-05-07 Ross Bridget A Sell 5,044 $111.10
2026-05-07 LeMaitre George W (Chairman and CEO) Sell 18,600 $107.64
2026-03-11 Kamke Trent G (Senior V. P., Operations) Sell 2,625 $108.50
2026-03-11 Roberts David B (President and Director) Sell 3,311.68 $107.68

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,656,867 shares shorted. With 21,307,125 shares available for purchase and an average trading volume over the past 10 trading days of 226,740, it would take at least 7.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1158895 4.9
2010 1158895 5.5
2011 1158895 1.5
2012 1158895 3.2
2013 1158895 3.6
2014 1158895 3.6
2015 1158895 9.6
2016 1158895 14.8
2017 1158895 19.8
2018 1158895 16.4
2019 1158895 10.5
2020 1158895 31
2021 1158895 30.9
2022 1158895 21.8
2023 1158895 32.3
2024 1158895 39.1
2025 1158895 75.4

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $374 million against net income of $296 million, or 1.26 times.

In 2025, operating cash flow was 1.41 times net income, compared with 1.61 times for the earliest three years (2009 to 2011).

In 2025, capital expenditures were $6.8 million, 8.3% of operating cash flow of $81.3 million, which leaves an estimated $74.5 million after capex. Across the 17 years with reported capex, it averaged 16.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 1.6 5.4 0.6 3.40
2010 6 7.1 2.5 1.17
2011 2.1 3.2 2 1.48
2012 2.6 4.7 1.2 1.84
2013 3.2 5.4 2.7 1.68
2014 3.9 5.5 1.2 1.41
2015 7.8 11.4 2.3 1.47
2016 10.6 16.9 2.8 1.60
2017 17.2 22.9 6.4 1.33
2018 22.9 19.5 3.1 0.85
2019 17.9 14.2 3.8 0.79
2020 21.2 34.8 3 1.64
2021 26.9 35.1 4.9 1.30
2022 20.6 25.4 3.2 1.23
2023 30.1 36.8 7.3 1.22
2024 44 44.1 7 1.00
2025 57.7 81.3 6.8 1.41

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $292 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $92.6 million, 31.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 1 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $0.7 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends paid were $18.1 million, 24.0% of estimated free cash flow of $75.4 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 14.8 3.3 0.3 3.6 24.5%
2017 19.8 4.2 0.8 5 25.1%
2018 16.4 5.4 0.7 6.2 37.8%
2019 10.5 6.7 0.7 7.4 70.6%
2020 31 7.7 0.6 8.3 26.7%
2021 30.9 9.3 0.8 10.1 32.8%
2022 21.8 11 0.6 11.6 53.4%
2023 32.3 12.4 0.9 13.3 41.1%
2024 39.1 14.4 1.7 16.1 41.2%
2025 75.4 18.1 1.8 19.9 26.4%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $50.9 million in 2009 and $250 million in 2025, a compound annual growth rate of 10.4% over 16 years.

Revenue rose 13.5% from 2024 to 2025.

Our estimated free cash flow was $75.4 million in 2025, 30.2% of revenue. In 2009 the estimated margin was 9.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 50.9 4.9 9.6%
2010 56.1 5.5 9.9%
2011 57.7 1.5 2.6%
2012 56.7 3.2 5.6%
2013 64.5 3.6 5.6%
2014 71.1 3.6 5.1%
2015 78.4 9.6 12.2%
2016 89.2 14.8 16.7%
2017 101 19.8 19.6%
2018 106 16.4 15.5%
2019 117 10.5 9.0%
2020 129 31 24.0%
2021 154 30.9 20.0%
2022 162 21.8 13.5%
2023 193 32.3 16.7%
2024 220 39.1 17.8%
2025 250 75.4 30.2%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $28.2 million against total liabilities of $222 million, or 12.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 36.1% of total assets in 2025, compared with 17.3% in 2010, an increase of 18.8 percentage points.

Stockholders equity was $394 million in 2025, compared with $52.4 million in 2010, a rise of 651.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 13.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 63.3 22.6 10.9 52.4
2011 59.7 20.1 7.6 52.1
2012 63.1 16.4 10.2 52.9
2013 70.5 14.7 13.9 56.6
2014 81.5 18.7 13.3 68.2
2015 90.7 27.5 12.8 77.9
2016 102 24.3 14.4 87.5
2017 126 19.1 16.6 110
2018 153 26.3 22.9 130
2019 188 11.8 40.2 148
2020 253 26.8 80.2 173
2021 293 13.9 38.7 254
2022 310 19.1 42.3 268
2023 347 24.3 48.9 298
2024 552 25.6 215 337
2025 616 28.2 222 394

Price Versus Our Estimated Value

Every one of the 17 fiscal years we have for LeMaitre Vascular under its current filer shows positive free cash flow.

At $73.61, LeMaitre Vascular trades above our fair value estimate of $17.20.

Free cash flow from the first three years of data averaged $4 million, and from the last three $48.9 million: a sharp rise.

Year-to-year variability in free cash flow is volatile, measured at 52%.

Its dividend yield is 1.27%.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 35% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 63% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to LeMaitre Vascular, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
LeMaitre Vascular (LMAT) 1,684 27.1 1.3% - 328% above
CONMED Corporation (CNMD) 1,382 19.2 - 5.6% 35% below
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above
IRadimed Corporation (IRMD) 1,036 43.3 1.0% - 995% above
Tactile Systems Technology (TCMD) 573 24.9 - - 162% above
InfuSystem Holdings (INFU) 287 32.6 - - 402% above
Utah Medical Products (UTMD) 198 20.8 1.7% 6.7% 75% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1158895.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: LMAT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in LMAT

Does LeMaitre Vascular have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: LMAT

This example shows how we apply the Trendshare checklist to LMAT: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 73.61
    • Market cap: $1.7B
    • EPS: 2.72
  2. Step 2 — Valuation checks

    • P/E: 27.062
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.